カテゴリ： GlobalData, アメリカ, 企業調査

HTG Molecular Diagnostics Inc (HTGM)：医療機器：M&Aディール及び事業提携情報

◆英語タイトル：HTG Molecular Diagnostics Inc (HTGM) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA904C11414
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：63
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
HTG Molecular Diagnostics Inc (HTG) is a technology company that provides molecular technology solutions. The company provides products such as HTG edge system, HTG edgeseq reagents and HTG edgeseq immuno-oncology biomarker panel assay, among others. It develops assays and reagent systems that provide quantitative gene expression analysis in formalin-fixed paraffin embedded tissue. HTG also offers endogenous control array, custom array development, qSelect miRNA gene list, qSelect mRNA gene list, qDiscovery miRNA Version 16, clinical trial support and ingenuity IPA data analysis services, among others. The company serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG is headquartered in Tucson, Arizona, the US.

HTG Molecular Diagnostics Inc (HTGM) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
HTG Molecular Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
HTG Molecular Diagnostics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
HTG Molecular Diagnostics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
HTG Molecular Diagnostics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
HTG Molecular Diagnostics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
HTG Molecular Diagnostics Inc, Medical Equipment, Deal Details 12
Venture Financing 12
HTG Molecular Diagnostics Raises USD18 Million in Venture Financing 12
HTG Molecular Diagnostics to Raise USD0.8 Million in Venture Financing 13
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 14
HTG Molecular Diagnostics Raises US$7.5 Million In Series E Financing 15
Partnerships 16
HTG Molecular Diagnostics and Firalis Enter into Licensing Agreement 16
HTG Molecular Diagnostics Enters Into Licensing Agreement With Centre of Excellence for Prevention of Organ Failure For COPD Prognostic Test 17
HTG Molecular Diagnostics Enters Into Licensing Agreement With Merck For Breast Cancer Marker Patent Portfolio 18
HTG Molecular Diagnostics to Enter into Agreement with QIAGEN 19
HTG Molecular Diagnostics Enters into Agreement with Merck 20
HTG Molecular Diagnostics Enters into Research Agreement with Instituto Valenciano de Oncologia 21
HTG Molecular Diagnostics Enters into Research Agreement with Centre Leon Berard 22
HTG Molecular Diagnostics Enters into Co-Development Agreement with Qiagen Manchester 23
HTG Molecular Diagnostics Enters into Agreement with Merck 24
HTG Molecular Diagnostics Amends Research Agreement with Bristol-Myers Squibb 25
HTG Molecular Diagnostics Enters into Distribution Agreement with Gamidor Diagnostics 26
HTG Molecular Diagnostics Enters into Agreement with Thermo Fisher Scientific 27
HTG Molecular Diagnostics Enters into Co-Development Agreement with Life Technologies 28
HTG Molecular Diagnostics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 29
HTG Molecular Diagnostics Amends its Agreement with Illumina to Develop IVD Kits for Sequencing Tests 30
HTG Molecular Diagnostics Enters Into Development Agreement With OvaGene Oncology 31
Proof Centre Enters Into Co-Development Agreement With HTG Molecular Diagnostics 32
HTG Molecular Diagnostics Enters Into Co-Marketing Agreement With John Wayne Cancer Institute 33
HTG Molecular Diagnostics Enters Into Co-Development Agreement With sanofi-aventis 34
Equity Offering 35
HTG Molecular Diagnostics Raises USD40 Million in Public Offering of Shares 35
HTG Molecular Diagnostics Prices IPO for USD50 Million 37
HTG Molecular Diagnostics Inc – Key Competitors 38
HTG Molecular Diagnostics Inc – Key Employees 39
HTG Molecular Diagnostics Inc – Locations And Subsidiaries 40
Head Office 40
Recent Developments 41
Financial Announcements 41
Aug 07, 2018: HTG Molecular Diagnostics reports second quarter 2018 results 41
May 10, 2018: HTG Molecular Diagnostics Reports First Quarter 2018 Results 42
Mar 22, 2018: HTG Molecular Diagnostics Announces Fourth Quarter And Full Year 2017 Results 43
Jan 04, 2018: HTG Announces Preliminary Fourth Quarter and Full Year 2017 Unaudited Financial Results and Provides Initial 2018 Revenue Guidance 44
Nov 07, 2017: HTG Molecular Diagnostics Reports 2017 Third Quarter Earnings 45
Aug 08, 2017: HTG Molecular Diagnostics Reports Second Quarter 2017 Results 46
May 15, 2017: HTG Molecular Diagnostics Reports First Quarter 2017 Results 47
Mar 23, 2017: HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2016 Results 48
Corporate Communications 49
Oct 31, 2018: HTG Molecular appoints Dr. Maureen T. Cronin as Chief Scientific Officer and Senior Vice President 49
Aug 16, 2018: HTG Molecular appoints Michelle R. Griffin to its board of directors 50
Apr 16, 2018: HTG Promotes John Lubniewski to President and Chief Operating Officer 51
Mar 07, 2017: HTG Molecular Diagnostics Appoints New Chair of the Board of Directors 52
Legal and Regulatory 53
Sep 18, 2017: HTG Molecular Diagnostics Receives ISO 13485 Certification for Health Canada CMDCAS Requirements 53
Government and Public Interest 54
Jan 10, 2018: University laboratory at Discovery Park is playing key role in early cancer detection research 54
Product News 56
Apr 03, 2018: HTG Announces New Patent for Its Technology Issued in Japan 56
Feb 26, 2018: HTG Announces New Australian Patent for Its Technology 57
Sep 20, 2017: HTG Announces Issuance of Two Method Patents Related to its Technology 58
May 04, 2017: HTG Molecular Diagnostics Introduces HTG EdgeSeq PATH Assay to Launch in Second Quarter 2017 59
Other Significant Developments 60
Sep 27, 2018: HTG Molecular announces extension to precision diagnostic partnership PDP program three for companion diagnostic submission 60
Aug 09, 2018: HTG Molecular announces amendment to second statement of work with QIAGEN Manchester 61
Feb 27, 2017: HTG Molecular Diagnostics Unveils New Direct-Target Sequencing Chemistry to Launch in First Quarter 2017 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63

List of Tables
HTG Molecular Diagnostics Inc, Medical Equipment, Key Facts, 2017 2
HTG Molecular Diagnostics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
HTG Molecular Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
HTG Molecular Diagnostics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
HTG Molecular Diagnostics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
HTG Molecular Diagnostics Inc, Deals By Market, 2012 to YTD 2018 9
HTG Molecular Diagnostics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
HTG Molecular Diagnostics Raises USD18 Million in Venture Financing 12
HTG Molecular Diagnostics to Raise USD0.8 Million in Venture Financing 13
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 14
HTG Molecular Diagnostics Raises US$7.5 Million In Series E Financing 15
HTG Molecular Diagnostics and Firalis Enter into Licensing Agreement 16
HTG Molecular Diagnostics Enters Into Licensing Agreement With Centre of Excellence for Prevention of Organ Failure For COPD Prognostic Test 17
HTG Molecular Diagnostics Enters Into Licensing Agreement With Merck For Breast Cancer Marker Patent Portfolio 18
HTG Molecular Diagnostics to Enter into Agreement with QIAGEN 19
HTG Molecular Diagnostics Enters into Agreement with Merck 20
HTG Molecular Diagnostics Enters into Research Agreement with Instituto Valenciano de Oncologia 21
HTG Molecular Diagnostics Enters into Research Agreement with Centre Leon Berard 22
HTG Molecular Diagnostics Enters into Co-Development Agreement with Qiagen Manchester 23
HTG Molecular Diagnostics Enters into Agreement with Merck 24
HTG Molecular Diagnostics Amends Research Agreement with Bristol-Myers Squibb 25
HTG Molecular Diagnostics Enters into Distribution Agreement with Gamidor Diagnostics 26
HTG Molecular Diagnostics Enters into Agreement with Thermo Fisher Scientific 27
HTG Molecular Diagnostics Enters into Co-Development Agreement with Life Technologies 28
HTG Molecular Diagnostics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 29
HTG Molecular Diagnostics Amends its Agreement with Illumina to Develop IVD Kits for Sequencing Tests 30
HTG Molecular Diagnostics Enters Into Development Agreement With OvaGene Oncology 31
Proof Centre Enters Into Co-Development Agreement With HTG Molecular Diagnostics 32
HTG Molecular Diagnostics Enters Into Co-Marketing Agreement With John Wayne Cancer Institute 33
HTG Molecular Diagnostics Enters Into Co-Development Agreement With sanofi-aventis 34
HTG Molecular Diagnostics Raises USD40 Million in Public Offering of Shares 35
HTG Molecular Diagnostics Prices IPO for USD50 Million 37
HTG Molecular Diagnostics Inc, Key Competitors 38
HTG Molecular Diagnostics Inc, Key Employees 39

List of Figures
HTG Molecular Diagnostics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
HTG Molecular Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
HTG Molecular Diagnostics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
HTG Molecular Diagnostics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
HTG Molecular Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
HTG Molecular Diagnostics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
HTG Molecular Diagnostics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
HTG Molecular Diagnostics Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[HTG Molecular Diagnostics Inc (HTGM)：医療機器：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Langley Holdings plc：企業の戦略・SWOT・財務分析
    Langley Holdings plc - Strategy, SWOT and Corporate Finance Report Summary Langley Holdings plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Curetis NV (CURE)：医療機器：M&Aディール及び事業提携情報
    Summary Curetis NV (Curetis) is a medical device company that offers molecular diagnosis solutions. The company provides diagnostic systems developed with Unyvero platform for severe infectious diseases. Its products are used in rapid diagnosis for cartridges, diseases such as implant and tissue inf …
  • Precision System Science Co Ltd (7707)-医療機器分野：企業M&A・提携分析
    Summary Precision System Science Co Ltd (PSS) is a medical device company that develops, manufactures and sells automated systems, physicochemical instruments, software, and others. The company’s products include automated nucleic acid isolation system, large sample volume nucleic acid extraction sy …
  • RattanIndia Power Ltd (RTNPOWER)：電力：M&Aディール及び事業提携情報
    Summary RattanIndia Power Ltd (RattanIndia Power), formerly Sophia Power Company Ltd is a power company that constructs, develops, operates, and manages thermal power projects across India. The company offers renewable energy solutions, operation and management of power plants, and project managemen …
  • SBM Offshore NV (SBMO)-石油・ガス分野：企業M&A・提携分析
    Summary SBM Offshore N.V. (SBM Offshore) is a floating production solutions provider for offshore oil and gas industry. The company designs supplies, installs and operates Floating Production, Storage and Offloading (FPSO) vessels. The company leases its FPSO vessels to its clients. It also undertak …
  • Klaria Pharma Holding AB (KLAR)：企業の財務・戦略的SWOT分析
    Summary Klaria Pharma Holding AB (Klaria Pharma) is a pharmaceutical company. It develops fast acting medicinal products for the treatment of cannabinoids, migraine, opioid overdose, anaphylactic shock, and cancer related pain. The company’s patented drug delivery platform features is an alginate ba …
  • Viking Line ABP：企業の戦略・SWOT・財務情報
    Viking Line ABP - Strategy, SWOT and Corporate Finance Report Summary Viking Line ABP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • PT Dahana：企業の戦略・SWOT・財務情報
    PT Dahana - Strategy, SWOT and Corporate Finance Report Summary PT Dahana - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Jacobs Engineering Group Inc (JEC)：電力：M&Aディール及び事業提携情報
    Summary Jacobs Engineering Group Inc (Jacobs) is a professional services company. It offers a diverse range of technical, professional, and construction services. The company's service portfolio includes project; process, scientific and specialty consulting; engineering and construction; and operati …
  • Pou Sheng International (Holdings) Ltd：戦略・SWOT・企業財務分析
    Pou Sheng International (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report Summary Pou Sheng International (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Taikisha Ltd：企業の戦略・SWOT・財務分析
    Taikisha Ltd - Strategy, SWOT and Corporate Finance Report Summary Taikisha Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Alliance MMA, Inc. (AMMA)：企業の財務・戦略的SWOT分析
    Alliance MMA, Inc. (AMMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • HomeServe plc (HSV)：企業の財務・戦略的SWOT分析
    HomeServe plc (HSV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • NUERNBERGER Beteiligungs-Aktiengesellschaft：企業の戦略・SWOT・財務情報
    NUERNBERGER Beteiligungs-Aktiengesellschaft - Strategy, SWOT and Corporate Finance Report Summary NUERNBERGER Beteiligungs-Aktiengesellschaft - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Oswaldo Cruz Foundation：製薬・医療：M&Aディール及び事業提携情報
    Summary Oswaldo Cruz Foundation (Oswaldo Cruz) is a provider of research and development in biological sciences. It offers research programs and technological development projects in vaccines production, medications, drugs, reagents and diagnostic kits. The foundation provides research in experiment …
  • Biosensors International Group Ltd：企業の戦略的SWOT分析
    Biosensors International Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • BP Plc (BP.)：電力：M&Aディール及び事業提携情報
    Summary BP Plc (BP) is an integrated oil and gas company. Its upstream activities include exploration, development and production of oil and natural gas, field development and production; and midstream operations include transportation, and marketing and trading of natural gas, including liquefied n …
  • Motiva Enterprises LLC：企業の戦略的SWOT分析
    Motiva Enterprises LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Enterome Bioscience SA：医療機器：M&Aディール及び事業提携情報
    Summary Enterome Bioscience SA (Enterome) is a drug development company which develops medical tests, and companion diagnostics to develop the management of microbiome-related diseases. The company develops medical tests based on its metagenotype technology platform that helps to identify microbiome …
  • LG International Corp (001120)：企業の財務・戦略的SWOT分析
    LG International Corp (001120) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆